FGFR4 and hepatocellular carcinoma: BLU-554 (also known as fisogatinib) is the most advanced of the clinically translatable FGFR4 inhibitors and is still being investigated in a phase I study for the treatment of advanced HCC (https://clinicaltrials.gov/ Identifier: NCT02508467).